{"entity":{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","aka":[],"tldr":"A phase 3 trial of Cyclophosphamide and Retifanlimab in advanced solid tumours, run by BriaCell Therapeutics Corporation, now recruiting.","summary":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. is a phase 3 interventional study registered as NCT06072612 by BriaCell Therapeutics Corporation, with 404 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-12. Interventions recorded: SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab and Treatment of Physician's Choice.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06072612","url":"https://clinicaltrials.gov/study/NCT06072612"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","retifanlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06072612","phase":"3","setting":"Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.","sponsor":"BriaCell Therapeutics Corporation","enrolled":404,"outcomes":[]},"route":"/trials/nct06072612/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/"}]}}